This company has been acquired
La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !
Taro Pharmaceutical Industries Performance dei guadagni passati
Il passato criteri di controllo 3/6
Taro Pharmaceutical Industries's earnings have been declining at an average annual rate of -15.7%, while the Pharmaceuticals industry saw earnings declining at 0.4% annually. Revenues have been declining at an average rate of 2.5% per year. Taro Pharmaceutical Industries's return on equity is 3%, and it has net margins of 8.6%.
Informazioni chiave
-15.7%
Tasso di crescita degli utili
-15.1%
Tasso di crescita dell'EPS
Pharmaceuticals Crescita del settore | 6.0% |
Tasso di crescita dei ricavi | -2.5% |
Rendimento del capitale proprio | 3.0% |
Margine netto | 8.6% |
Ultimo aggiornamento sui guadagni | 31 Mar 2024 |
Aggiornamenti sulle prestazioni recenti
Recent updates
Taro Pharmaceutical Industries Ltd. Is An Overlooked Opportunity
Dec 12Taro Pharmaceutical: Sun Pharma Deal Uncertain, No Discernible Value Beyond NAV (Rating Downgrade)
Aug 16Taro Pharmaceutical: Potential Value In Sun Pharma Offer
Jun 02Taro Pharmaceutical: Stagnating Growth At 1.6% Trailing Earnings Yield, Rate Hold
Feb 24Taro Pharmaceutical GAAP EPS of $0.19 misses by $0.68, revenue of $139.2M misses by $23.92M
Jan 24Taro Pharmaceutical Non-GAAP EPS of $0.66 misses by $0.18, revenue of $130.5M misses by $30.52M
Oct 28Taro Pharmaceutical hits 52-week low; down 28% YTD
Aug 15Taro Pharmaceutical Non-GAAP EPS of $1.09 beats by $0.24, revenue of $156.7M beats by $6.8M
Jul 27Taro Pharmaceutical: 10%+ Projected Earnings Yield Is A Strong Calling Card
Jul 14We Think Taro Pharmaceutical Industries' (NYSE:TARO) Healthy Earnings Might Be Conservative
Aug 03A Look At Taro Pharmaceutical Industries' (NYSE:TARO) Share Price Returns
Jan 26Ripartizione dei ricavi e delle spese
Come Taro Pharmaceutical Industries guadagna e spende denaro. In base agli ultimi utili dichiarati, su base LTM.
Storia dei guadagni e delle entrate
Data | Ricavi | Guadagni | Spese G+A | Spese di R&S |
---|---|---|---|---|
31 Mar 24 | 629 | 54 | 233 | 65 |
31 Dec 23 | 611 | 46 | 198 | 60 |
30 Sep 23 | 593 | 33 | 210 | 60 |
30 Jun 23 | 575 | 21 | 192 | 57 |
31 Mar 23 | 573 | 25 | 198 | 52 |
31 Dec 22 | 570 | 46 | 189 | 51 |
30 Sep 22 | 569 | 65 | 164 | 52 |
30 Jun 22 | 571 | 91 | 146 | 53 |
31 Mar 22 | 561 | 58 | 114 | 55 |
31 Dec 21 | 566 | 1 | 95 | 56 |
30 Sep 21 | 568 | 8 | 93 | 56 |
30 Jun 21 | 578 | 29 | 93 | 60 |
31 Mar 21 | 549 | -387 | 91 | 60 |
31 Dec 20 | 576 | -303 | 98 | 59 |
30 Sep 20 | 583 | -268 | 96 | 60 |
30 Jun 20 | 601 | -257 | 96 | 59 |
31 Mar 20 | 645 | 244 | 93 | 60 |
31 Dec 19 | 650 | 248 | 88 | 64 |
30 Sep 19 | 678 | 274 | 91 | 64 |
30 Jun 19 | 677 | 281 | 86 | 63 |
31 Mar 19 | 670 | 282 | 90 | 63 |
31 Dec 18 | 665 | 310 | 90 | 63 |
30 Sep 18 | 644 | 234 | 88 | 66 |
30 Jun 18 | 655 | 224 | 88 | 69 |
31 Mar 18 | 662 | 211 | 88 | 70 |
31 Dec 17 | 683 | 208 | 87 | 70 |
30 Sep 17 | 748 | 330 | 85 | 71 |
30 Jun 17 | 807 | 401 | 88 | 67 |
31 Mar 17 | 879 | 457 | 86 | 71 |
31 Dec 16 | 948 | 489 | 86 | 71 |
30 Sep 16 | 986 | 538 | 89 | 71 |
30 Jun 16 | 969 | 547 | 92 | 75 |
31 Mar 16 | 951 | 541 | 92 | 71 |
31 Dec 15 | 930 | 579 | 92 | 75 |
30 Sep 15 | 909 | 532 | 91 | 70 |
30 Jun 15 | 948 | 542 | 88 | 65 |
31 Mar 15 | 863 | 485 | 88 | 66 |
31 Dec 14 | 806 | 422 | 92 | 55 |
30 Sep 14 | 782 | 395 | 93 | 57 |
30 Jun 14 | 736 | 348 | 93 | 58 |
31 Mar 14 | 759 | 361 | 92 | 55 |
31 Dec 13 | 737 | 321 | 87 | 54 |
30 Sep 13 | 709 | 294 | 86 | 51 |
30 Jun 13 | 665 | 263 | 87 | 47 |
Guadagni di qualità: TARO has a large one-off gain of $14.2M impacting its last 12 months of financial results to 31st March, 2024.
Margine di profitto in crescita: TARO's current net profit margins (8.6%) are higher than last year (4.4%).
Flusso di cassa libero e analisi degli utili
Analisi della crescita degli utili nel passato
Andamento degli utili: TARO's earnings have declined by 15.7% per year over the past 5 years.
Accelerare la crescita: TARO's earnings growth over the past year (111.7%) exceeds its 5-year average (-15.7% per year).
Guadagni vs Settore: TARO earnings growth over the past year (111.7%) exceeded the Pharmaceuticals industry 19.9%.
Rendimento del capitale proprio
ROE elevato: TARO's Return on Equity (3%) is considered low.